{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:17:07Z","timestamp":1791389827017,"version":"4.3.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,17]]},"DOI":"10.7759\/cureus.67083","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T18:13:10Z","timestamp":1723918390000},"source":"Crossref","is-referenced-by-count":13,"title":["Silymarin as an Antioxidant Therapy in Chronic Liver Diseases: A Comprehensive Review"],"prefix":"10.7759","author":[{"given":"Devshree","family":"Dhande","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Dhok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Anjankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailesh","family":"Nagpure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/cld.1061","article-title":"Global epidemiology of chronic liver disease","volume":"17","author":"Cheemerla S","year":"2021","unstructured":"Cheemerla S, Balakrishnan M. Global epidemiology of chronic liver disease. Clin Liver Dis (Hoboken). 2021, 17:365-70. 10.1002\/cld.1061","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref2","article-title":"Chronic Liver Disease","author":"Sharma A","year":"2024","unstructured":"Sharma A, Nagalli S. Chronic Liver Disease. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101143","article-title":"Metabolic drivers of non-alcoholic fatty liver disease","volume":"50","author":"Bence KK","year":"2021","unstructured":"Bence KK, Birnbaum MJ. Metabolic drivers of non-alcoholic fatty liver disease. Mol Metab. 2021, 50:101143. 10.1016\/j.molmet.2020.101143","journal-title":"Mol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2069854","article-title":"Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review","volume":"54","author":"Aghemo A","year":"2022","unstructured":"Aghemo A, Alekseeva OP, Angelico F, et al.. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review. Ann Med. 2022, 54:1548-60. 10.1080\/07853890.2022.2069854","journal-title":"Ann Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2010.10.016","article-title":"Oxidative stress","volume":"25","author":"Burton GJ","year":"2011","unstructured":"Burton GJ, Jauniaux E. Oxidative stress. Best Pract Res Clin Obstet Gynaecol. 2011, 25:287-99. 10.1016\/j.bpobgyn.2010.10.016","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"ref6","article-title":"Milk Thistle","author":"Achufusi TGO","year":"2024","unstructured":"Achufusi TGO, Pellegrini MV, Patel RK. Milk Thistle. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/antiox4010204","article-title":"Silymarin as a natural antioxidant: an overview of the current evidence and perspectives","volume":"4","author":"Surai PF","year":"2015","unstructured":"Surai PF. Silymarin as a natural antioxidant: an overview of the current evidence and perspectives. Antioxidants (Basel). 2015, 4:204-47. 10.3390\/antiox4010204","journal-title":"Antioxidants (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01251-y","article-title":"Silymarin as supportive treatment in liver diseases: a narrative review","volume":"37","author":"Gillessen A","year":"2020","unstructured":"Gillessen A, Schmidt HH. Silymarin as supportive treatment in liver diseases: a narrative review. Adv Ther. 2020, 37:1279-301. 10.1007\/s12325-020-01251-y","journal-title":"Adv Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/fsn3.4010","article-title":"Silymarin: unveiling its pharmacological spectrum and therapeutic potential in liver diseases-a comprehensive narrative review","volume":"12","author":"Jaffar HM","year":"2024","unstructured":"Jaffar HM, Al-Asmari F, Khan FA, Rahim MA, Zongo E. Silymarin: unveiling its pharmacological spectrum and therapeutic potential in liver diseases-a comprehensive narrative review. Food Sci Nutr. 2024, 12:3097-111. 10.1002\/fsn3.4010","journal-title":"Food Sci Nutr"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.03.140","article-title":"Antioxidant effects and mechanism of silymarin in oxidative stress induced cardiovascular diseases","volume":"102","author":"Taleb A","year":"2018","unstructured":"Taleb A, Ahmad KA, Ihsan AU, et al.. Antioxidant effects and mechanism of silymarin in oxidative stress induced cardiovascular diseases. Biomed Pharmacother. 2018, 102:689-98. 10.1016\/j.biopha.2018.03.140","journal-title":"Biomed Pharmacother"},{"key":"ref11","article-title":"Silymarin\u201d, a promising pharmacological agent for treatment of diseases","volume":"14","author":"Karimi G","year":"2011","unstructured":"Karimi G, Vahabzadeh M, Lari P, Rashedinia M, Moshiri M. Silymarin\u201d, a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci. 2011, 14:308-17.","journal-title":"Iran J Basic Med Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3138\/canlivj-2023-0021","article-title":"Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis","volume":"7","author":"Malik A","year":"2024","unstructured":"Malik A, Malik M, Qureshi S. Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. Can Liver J. 2024, 7:40-53. 10.3138\/canlivj-2023-0021","journal-title":"Can Liver J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v5.i3.109","article-title":"Silymarin in non alcoholic fatty liver disease","volume":"5","author":"Cacciapuoti F","year":"2013","unstructured":"Cacciapuoti F, Scognamiglio A, Palumbo R, Forte R, Cacciapuoti F. Silymarin in non alcoholic fatty liver disease. World J Hepatol. 2013, 5:109-13. 10.4254\/wjh.v5.i3.109","journal-title":"World J Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.04.016","article-title":"A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis","volume":"15","author":"Wah Kheong C","year":"2017","unstructured":"Wah Kheong C, Nik Mustapha NR, Mahadeva S. A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2017, 15:1940-1949.e8. 10.1016\/j.cgh.2017.04.016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.47608","article-title":"Impact of silymarin supplements on liver enzyme levels: a systematic review","volume":"15","author":"Calderon Martinez E","year":"2023","unstructured":"Calderon Martinez E, Herrera D, Mogan S, et al.. Impact of silymarin supplements on liver enzyme levels: a systematic review. Cureus. 2023, 15:e47608. 10.7759\/cureus.47608","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9199190","article-title":"Effect of silymarin as an adjunct therapy in combination with sofosbuvir and ribavirin in hepatitis c patients: a miniature clinical trial","volume":"2022","author":"Ahmed S","year":"2022","unstructured":"Ahmed S, Ullah N, Parveen S, et al.. Effect of silymarin as an adjunct therapy in combination with sofosbuvir and ribavirin in hepatitis c patients: a miniature clinical trial. Oxid Med Cell Longev. 2022, 2022:9199190. 10.1155\/2022\/9199190","journal-title":"Oxid Med Cell Longev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/jfmk6030072","article-title":"Effect of silymarin supplementation in lung and liver histological modifications during exercise training in a rodent model","volume":"6","author":"Vargas-Mendoza N","year":"2021","unstructured":"Vargas-Mendoza N, Angeles-Valencia M, Morales-Gonz\u00e1lez \u00c1, et al.. Effect of silymarin supplementation in lung and liver histological modifications during exercise training in a rodent model. J Funct Morphol Kinesiol. 2021, 6:26-8. 10.3390\/jfmk6030072","journal-title":"J Funct Morphol Kinesiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07210-6","article-title":"Efficacy of silymarin in patients with non-alcoholic fatty liver disease - the Siliver trial: a study protocol for a randomized controlled clinical trial","volume":"24","author":"de Avelar CR","year":"2023","unstructured":"de Avelar CR, Nunes BV, da Silva Sassaki B, et al.. Efficacy of silymarin in patients with non-alcoholic fatty liver disease - the Siliver trial: a study protocol for a randomized controlled clinical trial. Trials. 2023, 24:177. 10.1186\/s13063-023-07210-6","journal-title":"Trials"},{"key":"ref19","article-title":"Milk Thistle (PDQ\u00ae): Health Professional Version","author":"PDQ Integrative","year":"2002","unstructured":"PDQ Integrative, Alternative, and Complementary Therapies Editorial Board. Milk Thistle (PDQ\u00ae): Health Professional Version. PDQ Cancer Information Summaries. National Cancer Institute (US), Bethesda, MD; 2002."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s11356-019-04146-w","article-title":"Asteraceae species as potential environmental factors of allergy","volume":"26","author":"Denisow-Pietrzyk M","year":"2019","unstructured":"Denisow-Pietrzyk M, Pietrzyk \u0141, Denisow B. Asteraceae species as potential environmental factors of allergy. Environ Sci Pollut Res Int. 2019, 26:6290-300. 10.1007\/s11356-019-04146-w","journal-title":"Environ Sci Pollut Res Int"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuro.2020.02.008","article-title":"Silymarin administration during pregnancy and breastfeeding: evaluation of initial development and adult behavior of mice","volume":"78","author":"Barbosa CC","year":"2020","unstructured":"Barbosa CC, Nishimura AN, Santos ML, Junior WD, Andersen ML, Mazaro-Costa R. Silymarin administration during pregnancy and breastfeeding: evaluation of initial development and adult behavior of mice. Neurotoxicology. 2020, 78:64-70. 10.1016\/j.neuro.2020.02.008","journal-title":"Neurotoxicology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-021-09666-w","article-title":"Hormonal treatments for endometriosis: the endocrine background","volume":"23","author":"Vannuccini S","year":"2022","unstructured":"Vannuccini S, Clemenza S, Rossi M, Petraglia F. Hormonal treatments for endometriosis: the endocrine background. Rev Endocr Metab Disord. 2022, 23:333-55. 10.1007\/s11154-021-09666-w","journal-title":"Rev Endocr Metab Disord"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24203693","article-title":"Metabolism, transport and drug-drug interactions of silymarin","volume":"24","author":"Xie Y","year":"2019","unstructured":"Xie Y, Zhang D, Zhang J, Yuan J. Metabolism, transport and drug-drug interactions of silymarin. Molecules. 2019, 24:42-4. 10.3390\/molecules24203693","journal-title":"Molecules"},{"key":"ref24","article-title":"Warfarin","author":"Patel S","year":"2024","unstructured":"Patel S, Singh R, Preuss CV, Patel N. Warfarin. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009347475","article-title":"Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C","volume":"50","author":"Hawke RL","year":"2010","unstructured":"Hawke RL, Schrieber SJ, Soule TA, et al.. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol. 2010, 50:434-49. 10.1177\/0091270009347475","journal-title":"J Clin Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/antiox8080317","article-title":"Complex evaluation of antioxidant capacity of milk thistle dietary supplements","volume":"8","author":"Viktorova J","year":"2019","unstructured":"Viktorova J, Stranska-Zachariasova M, Fenclova M, Vitek L, Hajslova J, Kren V, Ruml T. Complex evaluation of antioxidant capacity of milk thistle dietary supplements. Antioxidants (Basel). 2019, 8:7-9. 10.3390\/antiox8080317","journal-title":"Antioxidants (Basel)"},{"key":"ref27","article-title":"Alcoholic Liver Disease","author":"Patel R","year":"2024","unstructured":"Patel R, Mueller M. Alcoholic Liver Disease. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24112155","article-title":"Formulation strategies for enhancing the bioavailability of silymarin: the state of the art","volume":"24","author":"Di Costanzo A","year":"2019","unstructured":"Di Costanzo A, Angelico R. Formulation strategies for enhancing the bioavailability of silymarin: the state of the art. Molecules. 2019, 24:14-6. 10.3390\/molecules24112155","journal-title":"Molecules"},{"key":"ref29","article-title":"Clinical and research information on drug-induced liver injury","year":"2012","unstructured":"LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2012. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548733\/."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2010.541579","article-title":"Comparative effects of silymarin and vitamin E supplementation on oxidative stress markers, and hemoglobin levels among patients on hemodialysis","volume":"33","author":"Roozbeh J","year":"2011","unstructured":"Roozbeh J, Shahriyari B, Akmali M, et al.. Comparative effects of silymarin and vitamin E supplementation on oxidative stress markers, and hemoglobin levels among patients on hemodialysis. Ren Fail. 2011, 33:118-23. 10.3109\/0886022X.2010.541579","journal-title":"Ren Fail"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56100544","article-title":"Silymarin in combination with vitamin C, vitamin E, coenzyme Q10 and selenomethionine to improve liver enzymes and blood lipid profile in NAFLD patients","volume":"56","author":"Curcio A","year":"2020","unstructured":"Curcio A, Romano A, Cuozzo S, et al.. Silymarin in combination with vitamin C, vitamin E, coenzyme Q10 and selenomethionine to improve liver enzymes and blood lipid profile in NAFLD patients. Medicina (Kaunas). 2020, 56:32-4. 10.3390\/medicina56100544","journal-title":"Medicina (Kaunas)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jff.2023.105502","article-title":"Critical review of therapeutic potential of silymarin in cancer: a bioactive polyphenolic flavonoid","volume":"104","author":"Koushki M","year":"2023","unstructured":"Koushki M, Farrokhi Yekta R, Amiri-Dashatan N. Critical review of therapeutic potential of silymarin in cancer: a bioactive polyphenolic flavonoid. J Funct Foods. 2023, 104:105502. 10.1016\/j.jff.2023.105502","journal-title":"J Funct Foods"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastha.2022.05.006","article-title":"Silymarin for treating toxic liver disease: international consensus recommendations","volume":"1","author":"Gillessen A","year":"2022","unstructured":"Gillessen A, Angelico F, Chen J, et al.. Silymarin for treating toxic liver disease: international consensus recommendations. Gastro Hep Adv. 2022, 1:882-93. 10.1016\/j.gastha.2022.05.006","journal-title":"Gastro Hep Adv"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1186\/s40816-016-0019-2","article-title":"The potential of silymarin for the treatment of hepatic disorders","volume":"2","author":"Hellerbrand C","year":"2016","unstructured":"Hellerbrand C, Schattenberg JM, Peterburs P, Lechner A, Brignoli R. The potential of silymarin for the treatment of hepatic disorders. Clin Phytosci. 2016, 2:7. 10.1186\/s40816-016-0019-2","journal-title":"Clin Phytosci"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i18.2288","article-title":"Silybin and the liver: from basic research to clinical practice","volume":"17","author":"Loguercio C","year":"2011","unstructured":"Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J Gastroenterol. 2011, 17:2288-301. 10.3748\/wjg.v17.i18.2288","journal-title":"World J Gastroenterol"},{"key":"ref36","article-title":"Silymarin in treatment of non-alcoholic steatohepatitis: a randomized clinical trial","volume":"5","author":"Solhi H","year":"2014","unstructured":"Solhi H, Ghahremani R, Kazemifar AM, Hoseini Yazdi Z. Silymarin in treatment of non-alcoholic steatohepatitis: a randomized clinical trial. Caspian J Intern Med. 2014, 5:9-12.","journal-title":"Caspian J Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/285871-silymarin-as-an-antioxidant-therapy-in-chronic-liver-diseases-a-comprehensive-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T18:13:14Z","timestamp":1723918394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/285871-silymarin-as-an-antioxidant-therapy-in-chronic-liver-diseases-a-comprehensive-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,17]]},"references-count":36,"URL":"https:\/\/doi.org\/10.7759\/cureus.67083","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,17]]}}}